Pfizer announces positive results from Phase 3 Study of Abrysvo
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
Total value of the supplies of FC will be US$ 2.773 million
Aims to become a leading global partner for botanical extracts and natural actives in the beauty and personal care market
Fluid bed processes: drying, granulating, and coating in just one product container
Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research (AACR) annual meeting on Monday, April 8 and highlighted as part of the official meeting press program
The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Prozac Tablets of Eli Lilly
The company will respond to the Warning Letter within the stipulated timelines
Empowering Research, Enhancing Proficiency is the theme of this year’s Homoeopathic Symposium
Subscribe To Our Newsletter & Stay Updated